Patients with advanced prostate cancer (PCa) receive androgen receptor (NR3C4/AR) signaling inhibitors (ARSI), such as such Enzalutamide (Enza), which are initially successful but recurrent PCa frequently emerges (reviewed in(1)). Here, AR is linked to prostate carcinoma.